Hansen M M, Andersen E, Christensen B E, Christiansen I, Geisler C, Kristensen D, Jensen K B, Junker P
Finsen Institute/Rigshospitalet, Copenhagen, Denmark.
Nouv Rev Fr Hematol (1978). 1988;30(5-6):433-6.
Five hundred and fifty consecutive patients with newly diagnosed B-CLL have been registered and classified in a Danish multicenter study. The study includes a protocol for primary treatment of patients in stage B or C (at diagnosis or after demonstrated progression), below 76 years of age, and without complicating serious disease. Until now 144 such patients have been randomized to either prednisolone (PRD) plus chlorambucil (CLB) 5 days every 4 weeks or monthly intensive CHOP treatment. Twenty-nine percent of the treated patients achieved CR on PRD + CLB versus 63% on CHOP (p less than 0.005). No response was found in 29% versus 18%, respectively (NS). A significant difference in survival between patients achieving CR, PR and NR was also demonstrated, whereas to date no difference in survival could be demonstrated between the two regimens. The toxicity was limited, and only 2 treatment-related deaths occurred in approximately 700 CHOP treatment series.
在一项丹麦多中心研究中，对550例新诊断的B细胞慢性淋巴细胞白血病患者进行了登记和分类。该研究包括一项针对B期或C期患者（诊断时或病情进展后）、年龄在76岁以下且无严重并发症疾病的初始治疗方案。到目前为止，144例此类患者被随机分为两组，一组每4周接受5天的泼尼松龙（PRD）加苯丁酸氮芥（CLB）治疗，另一组接受每月一次的强化CHOP治疗。接受PRD + CLB治疗的患者中有29%达到完全缓解（CR），而接受CHOP治疗的患者中这一比例为63%（p < 0.005）。分别有29%和18%的患者无反应（无统计学差异）。达到CR、部分缓解（PR）和未缓解（NR）的患者在生存率上也存在显著差异，而迄今为止，两种治疗方案在生存率上未显示出差异。毒性有限，在大约700个CHOP治疗疗程中仅发生了2例与治疗相关的死亡。
